Vanguard Group’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-1,536,333
Closed -$27.6M 4134
2017
Q4
$27.6M Sell
1,536,333
-95,080
-6% -$1.17M ﹤0.01% 2361
2017
Q3
$19.3M Sell
1,631,413
-14,935
-0.9% -$168K ﹤0.01% 2504
2017
Q2
$17.3M Buy
1,646,348
+189,561
+13% +$1.93M ﹤0.01% 2523
2017
Q1
$16M Buy
1,456,787
+478,226
+49% +$5.55M ﹤0.01% 2538
2016
Q4
$13.3M Buy
978,561
+9,339
+1% +$130K ﹤0.01% 2612
2016
Q3
$11.9M Sell
969,222
-199,193
-17% -$2.35M ﹤0.01% 2603
2016
Q2
$12.8M Sell
1,168,415
-772,197
-40% -$8.64M ﹤0.01% 2529
2016
Q1
$21.2M Sell
1,940,612
-8,676
-0.4% -$110K ﹤0.01% 2281
2015
Q4
$33.7M Buy
1,949,288
+281,516
+17% +$5.05M ﹤0.01% 2072
2015
Q3
$33.1M Buy
1,667,772
+733,279
+78% +$16.8M ﹤0.01% 2059
2015
Q2
$15.4M Buy
934,493
+236,655
+34% +$4.1M ﹤0.01% 2469
2015
Q1
$10.9M Buy
697,838
+126,074
+22% +$1.95M ﹤0.01% 2607
2014
Q4
$8.16M Sell
571,764
-55,237
-9% -$583K ﹤0.01% 2636
2014
Q3
$4.08M Buy
627,001
+10,784
+2% +$71.6K ﹤0.01% 2939
2014
Q2
$4.25M Buy
616,217
+66,123
+12% +$468K ﹤0.01% 2919
2014
Q1
$3.93M Buy
550,094
+52,777
+11% +$452K ﹤0.01% 2947
2013
Q4
$4.67M Sell
497,317
-47,809
-9% -$341K ﹤0.01% 2839
2013
Q3
$3.4M Sell
545,126
-22,451
-4% -$140K ﹤0.01% 2925
2013
Q2
$3.73M Buy
+567,577
New +$4.5M ﹤0.01% 2819

Other funds holding SCMP

Vanguard Group's SCMP Position: Q1 2018 in Review

Vanguard Group sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 1,536,333 shares — an estimated $27.6M sold.

Vanguard Group first reported a position in SCMP in Q2 2013 and held it in 19 quarters. The position peaked at $33.7M in Q4 2015. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

  • Vanguard Group reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Vanguard Group sold 1,536,333 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $27.6M.
  • Vanguard Group first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 19 quarters.
  • Vanguard Group's Sucampo Pharmaceuticals, Inc. position peaked at $33.7M in Q4 2015.
  • 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Vanguard Group's 13F filing for Q1 2018, filed 15 May 2018.